about
Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulationVav is associated with signal transducing molecules gp130, Grb2 and Erk2, and is tyrosine phosphorylated in response to interleukin-6Structure and function of a new STAT-induced STAT inhibitorIL-6 in inflammation, immunity, and diseaseDifferential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity.Oligo-guanosine nucleotide induces neuropilin-1 internalization in endothelial cells and inhibits angiogenesisThe skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.Effect of enzymatically modified isoquercitrin, a flavonoid, on symptoms of Japanese cedar pollinosis: a randomized double-blind placebo-controlled trial.Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3ASulfated polysaccharides identified as inducers of neuropilin-1 internalization and functional inhibition of VEGF165 and semaphorin3ASialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis.Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications.Fungal ITS1 Deep-Sequencing Strategies to Reconstruct the Composition of a 26-Species Community and Evaluation of the Gut Mycobiota of Healthy Japanese Individuals.Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.Therapeutic targeting of the interleukin-6 receptor.A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.The role and therapeutic targeting of IL-6 in rheumatoid arthritis.Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoimmune vasculitis.Immunotherapeutic implications of IL-6 blockade for cytokine storm.Regulation of IL-6 in Immunity and Diseases.Regulation of intestinal homeostasis by the ulcerative colitis-associated gene RNF186.LRRK1 is critical in the regulation of B-cell responses and CARMA1-dependent NF-κB activation.Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.Immune reconstitution inflammatory syndrome in a patient with adult-onset Still's disease: graft-versus-host-like skin reaction with possible asymptomatic human herpes virus reactivation during steroid tapering.Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway.Viral interleukin 6 stimulates human peripheral blood B cells that are unresponsive to human interleukin 6.Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine.Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus.A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.The Two-Faced Cytokine IL-6 in Host Defense and DiseasesReceptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirusNeuropilin-2: a new molecular target for antiangiogenic and antitumor strategiesWhat kind of durometer is best suited for the assessment of skin disease in systemic sclerosis? Comment on the article by Kissin et alTargeting coagulation to the tumor microvasculature: perspectives and therapeutic implications from preclinical studiesImprovement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumabTumor cell populations differ in angiogenic activity: a model system for spontaneous angiogenic switch can tell us whySustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritisConflicting results from clinical observations and murine models: what is the role of plasminogen activators in tumor growth?Therapeutic effect of tocilizumab on two patients with polymyositis
P50
Q24670416-8C083DC1-8585-4F19-BC94-F6AACEE2940FQ28302502-8F9CDC7F-973B-466D-B0B3-B95115DAA356Q28584775-4A7331F3-76F2-4011-A5D5-2E7299AB48EFQ34248105-B9B1F49A-0E96-41C2-9D86-7272B03FB984Q34267273-5FBC6160-22E0-466B-BE75-EA3B8B2AAD68Q34282386-B3088A82-5672-41FE-B50C-FE3BF516C4CDQ34310749-E8DBC0D9-A656-421C-89C3-3DC2D7E49F44Q34605542-6477D36F-1DF0-4804-A0D8-2D4160EBE5CDQ35848293-C7B04A7C-E61D-4523-AD18-F3E2585967FDQ36528775-245F92F4-316B-4B8F-B56E-E4CEFF7FB4C8Q36768842-70813C19-E9C3-4043-AD31-8471DBBBA71EQ37275562-89E70DCE-0077-4DF1-AF76-A3A34863B908Q37642262-1974B238-30A4-40C9-AF1F-3774E92C501FQ37854935-5A6432CD-6FA3-4E78-A4F7-3CAC20F10242Q37930662-C15E4A97-46F4-48F9-9898-7EC708ABDD60Q38193230-C175A4E9-6296-40B6-8773-0227F91CDED9Q38685086-39BFF023-F5A7-4B15-9EF2-2DD2FEE180E6Q38707220-5088E82F-C1F6-4149-9A80-653EAEEC5D17Q38887311-A65BF8F8-1564-4C97-B44A-3590626D2A6AQ40508670-7143ED02-9383-46D0-9937-ED472DC25C69Q40624224-373183F7-B048-4FD9-B45A-D0ABFEEC813CQ41343171-C47B98BE-9161-482A-9827-2E65AF33B4F0Q43233229-49761FCD-D2E9-475E-B688-CC402D515112Q43444262-569087BA-68DF-4960-AA6C-1D553E173B3AQ45348556-C258390E-DB9B-46C9-AECA-2A64B3E6157EQ45944887-BCC1E2E5-409F-4B44-BD29-543FAF32EDF3Q46038841-0A2A59E2-EBFB-477E-8509-1A475529F7F1Q46470525-1F562EB0-99CC-4652-893F-3C8363908998Q47140249-BABDB826-294A-4090-89A5-15F50012D51AQ51439320-441BF90D-01CE-43A5-8839-BDBA03DB21D8Q59793706-E4B1B79B-1936-4DBA-A25B-607430E31DDAQ77136406-DFE86681-3592-47CF-9B88-3816F1BAE493Q80465604-F5342844-8B32-49D4-8E3D-F6BB5382C2FCQ81001051-06962081-86B4-4DDD-BBD9-16B079A3857DQ81757130-C2E6187B-EA37-47B7-BDD6-6238E85B3B3AQ82079424-79763F8C-DE9C-4E0F-9D80-F5EBE4E4CCB0Q82686589-34229829-B45F-4DD7-BE55-A4E632D865B7Q83075901-52B83F08-FA5D-4873-AD68-669584950A13Q83938865-606AF394-0F38-49A3-8B9D-432A51752308Q83941483-5CC0FF0A-691C-463E-BAB5-0DF2A98B751D
P50
description
researcher ORCID ID = 0000-0002-5613-4409
@en
wetenschapper
@nl
name
Masashi Narazaki
@ast
Masashi Narazaki
@en
Masashi Narazaki
@es
Masashi Narazaki
@nl
type
label
Masashi Narazaki
@ast
Masashi Narazaki
@en
Masashi Narazaki
@es
Masashi Narazaki
@nl
prefLabel
Masashi Narazaki
@ast
Masashi Narazaki
@en
Masashi Narazaki
@es
Masashi Narazaki
@nl
P106
P1153
7004556201
P31
P496
0000-0002-5613-4409